Acute myeloid leukaemia: challenges and real world data from India

Philip, Chepsy ; George, Biju ; Ganapule, Abhijeet ; Korula, Anu ; Jain, Punit ; Alex, Ansu Abu ; Lakshmi, Kavitha M. ; Sitaram, Usha ; Abubacker, Fouzia N. ; Abraham, Aby ; Viswabandya, Auro ; Srivastava, Vivi M. ; Srivastava, Alok ; Balasubramanian, Poonkuzhali ; Mathews, Vikram (2015) Acute myeloid leukaemia: challenges and real world data from India British Journal of Haematology, 170 (1). pp. 110-117. ISSN 0007-1048

Full text not available from this repository.

Official URL:

Related URL:


The management of acute myeloid leukaemia (AML) in India remains a challenge. In a two‐year prospective study at our centre there were 380 newly diagnosed AML (excluding acute promyelocytic leukaemia, AML‐M3) patients. The median age of newly diagnosed patients was 40 years (range: 1–79; 12·3% were ≤ 15 years, 16·3% were ≥ 60 years old) and there were 244 (64·2%) males. The median duration of symptoms prior to first presentation at our hospital was 4 weeks (range: 1–52). The median distance from home to hospital was 580 km (range: 6–3200 km). 109 (29%) opted for standard of care and were admitted for induction chemotherapy. Of the 271 that did not take treatment the major reason was lack of financial resources in 219 (81%). There were 27 (24·7%) inductions deaths and of these, 12 (44·5%) were due to multidrug‐resistant gram‐negative bacilli and 12 (44·5%) showed evidence of a fungal infection. The overall survival at 1 year was 70·4% ± 10·7%, 55·6% ± 6·8% and 42·4% ± 15·6% in patients aged ≤15 years, 15 ‐ 60 years and ≥60 years, respectively. In conclusion, the biggest constraint is the cost of treatment and the absence of a health security net to treat all patients with this diagnosis.

Item Type:Article
Source:Copyright of this article belongs to John Wiley and Sons, Inc.
ID Code:113605
Deposited On:07 Jun 2018 11:26
Last Modified:07 Jun 2018 12:21

Repository Staff Only: item control page